Endothelial progenitor cells: therapeutic target for cardiovascular diseases - PubMed (original) (raw)
Review
doi: 10.1254/jphs.08r01cp. Epub 2008 Sep 6.
Affiliations
- PMID: 18776710
- DOI: 10.1254/jphs.08r01cp
Free article
Review
Endothelial progenitor cells: therapeutic target for cardiovascular diseases
Takashi Umemura et al. J Pharmacol Sci. 2008 Sep.
Free article
Abstract
Circulating endothelial progenitor cells (EPCs) derived from bone marrow were isolated for the first time in 1997 and characterized. Recent evidence has indicated that EPCs contribute to re-endothelialization of injured vessels as well as neovascularization of ischemic lesions and that a decrease in the number of EPCs is an independent predictor of morbidity and mortality of cardiovascular diseases. These finding suggest that EPCs play a major role in the pathogenesis of atherosclerosis and cardiovascular diseases. Interestingly, the number and function of EPCs are regulated by not only various kinds of angiogenic cytokines and cardiovascular risk factors per se but also some interventions, including lifestyle modification (aerobic exercise, body weight loss, and smoking cessation) and pharmacological therapy (e.g., renin-angiotensin system inhibitor, statin, and erythropoietin). It is thought that regulation of the number and function of EPCs directly influences the maintenance and development of atherosclerosis. Therefore, it is clinically important to estimate the degree of EPC bioactivity and to increase the EPC bioactivity by appropriate interventions. In this review, we focus on the relationship between EPCs and cardiovascular risk factors and the role of EPCs in cardiovascular diseases.
Similar articles
- Hypoxia inducible factor-1 alpha, endothelial progenitor cells, monocytes, cardiovascular risk, wound healing, cobalt and hydralazine: a unifying hypothesis.
Hoenig MR, Bianchi C, Sellke FW. Hoenig MR, et al. Curr Drug Targets. 2008 May;9(5):422-35. doi: 10.2174/138945008784221215. Curr Drug Targets. 2008. PMID: 18473772 Review. - Stimulation of endothelial progenitor cells: a new putative effect of several cardiovascular drugs.
António N, Fernandes R, Rodriguez-Losada N, Jiménez-Navarro MF, Paiva A, de Teresa Galván E, Gonçalves L, Ribeiro CF, Providência LA. António N, et al. Eur J Clin Pharmacol. 2010 Mar;66(3):219-30. doi: 10.1007/s00228-009-0764-y. Epub 2009 Dec 10. Eur J Clin Pharmacol. 2010. PMID: 20012029 Review. - Circulating endothelial progenitor cells characterization, function and relationship with cardiovascular risk factors.
Balbarini A, Barsotti MC, Di Stefano R, Leone A, Santoni T. Balbarini A, et al. Curr Pharm Des. 2007;13(16):1699-713. doi: 10.2174/138161207780831329. Curr Pharm Des. 2007. PMID: 17584100 Review. - Endothelial progenitor cells as potential drug targets.
Thum T, Bauersachs J. Thum T, et al. Curr Drug Targets Cardiovasc Haematol Disord. 2005 Aug;5(4):277-86. doi: 10.2174/1568006054553435. Curr Drug Targets Cardiovasc Haematol Disord. 2005. PMID: 16101561 Review. - Endothelial progenitor cells in cardiovascular disorders.
Shantsila E, Watson T, Lip GY. Shantsila E, et al. J Am Coll Cardiol. 2007 Feb 20;49(7):741-52. doi: 10.1016/j.jacc.2006.09.050. J Am Coll Cardiol. 2007. PMID: 17306702 Review.
Cited by
- Calcitonin gene-related peptide released from endothelial progenitor cells inhibits the proliferation of rat vascular smooth muscle cells induced by angiotensin II.
Fang L, Chen MF, Xiao ZL, Liu Y, Yu GL, Chen XB, Xie XM. Fang L, et al. Mol Cell Biochem. 2011 Sep;355(1-2):99-108. doi: 10.1007/s11010-011-0843-0. Epub 2011 May 21. Mol Cell Biochem. 2011. PMID: 21603886 - Endothelial progenitor cells and vascular dysfunction in children with obstructive sleep apnea.
Kheirandish-Gozal L, Bhattacharjee R, Kim J, Clair HB, Gozal D. Kheirandish-Gozal L, et al. Am J Respir Crit Care Med. 2010 Jul 1;182(1):92-7. doi: 10.1164/rccm.200912-1845OC. Epub 2010 Mar 4. Am J Respir Crit Care Med. 2010. PMID: 20203242 Free PMC article. - Effects of the factor Xa inhibitor rivaroxaban on the differentiation of endothelial progenitor cells.
Sohma R, Sakuma M, Obi S, Nishino S, Inoue KI, Kishimoto S, Lu T, Toyoda S, Inoue T. Sohma R, et al. BMC Cardiovasc Disord. 2023 Jun 2;23(1):282. doi: 10.1186/s12872-023-03318-4. BMC Cardiovasc Disord. 2023. PMID: 37268884 Free PMC article. - Bone marrow endothelial progenitors augment atherosclerotic plaque regression in a mouse model of plasma lipid lowering.
Yao L, Heuser-Baker J, Herlea-Pana O, Iida R, Wang Q, Zou MH, Barlic-Dicen J. Yao L, et al. Stem Cells. 2012 Dec;30(12):2720-31. doi: 10.1002/stem.1256. Stem Cells. 2012. PMID: 23081735 Free PMC article. - Mesenchymal stem cell: present challenges and prospective cellular cardiomyoplasty approaches for myocardial regeneration.
Paul D, Samuel SM, Maulik N. Paul D, et al. Antioxid Redox Signal. 2009 Aug;11(8):1841-55. doi: 10.1089/ars.2009.2455. Antioxid Redox Signal. 2009. PMID: 19260767 Free PMC article. Review.